New from NCI |
Trastuzumab May Help Women with Rare Endometrial Cancer Live Longer |
| | A small clinical trial suggests that some women with an aggressive type of endometrial cancer may live longer if they receive a drug that is often used to treat breast cancer with high levels of the HER2 protein. |
Health Problems among Teen and Young Adult Cancer Survivors |
| | A study found that cancer survivors who were diagnosed as teens or young adults are more likely to develop a wide range of health problems than their peers who had not had cancer. |
Fusion Proteins in Childhood Cancers |
| | Fusion proteins occur in cells in which a piece of one chromosome breaks off and attaches to another chromosome. Learn more about research on fusion proteins that drive the growth of many childhood cancers. |
New Treatments Lead to Drop in Lung Cancer Mortality
The number of deaths from non-small cell lung cancer (NSCLC) has fallen sharply in recent years. A new study led by NCI researchers shows that the drop is most likely due to new targeted treatments and fewer new cases of NSCLC. |
Video—NCI Cancer Research Data Commons
The NCI Cancer Research Data Commons helps scientists share and analyze data. Learn how this resource will help make progress against cancer.
|
FDA Approvals |
New Drug for Diffuse Large B-Cell Lymphoma
We’ve added a new drug summary for tafasitamab-cxix (Monjuvi). It was recently approved by the Food and Drug Administration to treat certain types of relapsed or refractory diffuse large B-cell lymphoma in adults who cannot receive an autologous stem cell transplant. |
No hay comentarios:
Publicar un comentario